The Department of Public Health of the United Kingdom announced on Monday that the initial dose of vaccines produced by Pfizer and BioNTech could reduce the risk of coronavirus infection, as British Prime Minister Boris Johnson confirmed plans to relax the lockdown rules.
According to data released by Johnson when he began his speech in Congress, a dose of a vaccine from Pfizer PFE, a US pharmaceutical company, was targeted at healthcare workers under 65.
And its partner BioNTech BNTX,
The risk of infection was reduced by more than 70% and rose to 85% after the second dose.
For people over 80 years old, after three to four weeks of vaccination, the effective rate of one dose against symptomatic COVID-19 disease is 57%, and after the second dose it rises to over 85%.
Public Health England added that early data suggest that vaccinators who continue to be infected are much less likely to die or be hospitalized.
The UK is the first country to start using Pfizer-BioNTech vaccine. So far, the focus of the vaccination campaign has been on the elderly and frontline medical staff.
The UK is also unique in choosing to delay the second Pfizer-BioNTech dosing time to 12 weeks. Pfizer’s own experiments show that the dosing interval is 21 days.
The health agency said there was “good” evidence that the second dose of vaccine came from the drug company AstraZeneca AZN.
Later, Oxford University will provide a higher level of protection. Johnson said it is too early to provide precise data on the vaccine.
Public Health Scotland separately stated that its own research found that the Pfizer-BioNTech vaccine can reduce the risk of hospitalization by up to 85%, while the AstraZeneca-Oxford vaccine can reduce the risk of hospitalization by up to 94%.
The significance of these studies is that they are conducted in a real-world environment, as opposed to controlled studies controlled by drug manufacturers.